# US 2003/0077294 A1 · Antigenic preparations and isolation of such preparations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077294 A1
- Document ID: US20030077294A1
- Status: Published application
- Kind: A1
- Application number: 10/243,930
- Filed: 2002-09-16
- Published: 2003-04-24
- Earliest claimed: 1984-05-12
- Assignees: Medeva Pharma Limited
- Inventors: Pavel Novotny; Juan Antonio Montaraz Crespo; Juraj Ivanyi
- Web page: https://patentgrep.com/patent/US20030077294A1

## CPC

- C07K 14/235: from Bordetella (G)
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- C12N 9/88: Lyases (4.)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- Y10S 530/806: Antigenic peptides or proteins
- Y10S 530/825: Bacteria
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention provides novel antigenic preparations comprising proteinaceous material associated with adenylate cyclase activity in cultures of B.pertussis, the said preparations being useful as components of acellular whooping cough vaccines. The invention further provides methods for the isolation of such antigenic preparations.

## Claims

### Claim 1

A vaccine formulation for protection against Bordetella pertussis which includes an antigenic preparation derived from B. pertussis comprising proteinaceous material associated with adenylate cyclase activity (ACAP) together with a pharmaceutically acceptable carrier therefor.

### Claim 2 (depends on 1)

A vaccine formulation as claimed in claim 1 wherein the said ACAP has a relative molecular weight (MW) of 67,000-73,000.

### Claim 3 (depends on 1)

A vaccine formulation according to claim 1 wherein the said ACAP has a MW of substantially 69,000.

### Claim 4 (depends on 1)

A vaccine formulation according to claim 1 wherein the said ACAP has an isoelectric point (pl) of 7.0-7.4 under preparative isoelectric focussing (IEF) conditions.

### Claim 5 (depends on 4)

A vaccine formulation according to claim 4 wherein the said ACAP has a pl of substantially 7.0.

### Claim 6 (depends on 1)

A vaccine formulation according to claim 1 wherein the ratio of proline to glutamic acid residues in the said ACAP is substantially 1:1.

### Claim 7 (depends on 1)

A vaccine formulation according to claim 1 wherein the tyrosine residues contained in the said ACAP are not iodinctable.

### Claim 8 (depends on 1)

A vaccine formulation according to claim 1 substantially free from intracelluler material derived from B.pertussis.

### Claim 9 (depends on 1)

A vaccine formulation according to claim 1 further comprising a pharmaceutically acceptable adjuvant.

### Claim 10 (depends on 1)

A vaccine formulation according to claim 1 further comprising one or more other antigenic components.

### Claim 11

A method for the isolation of an antigenic preparation containing ACAP from B. pertussis which comprises treating a culture of B.pertussis cells with an aqueous amino acid buffer of pH 2.5-3.5, comprising a hypertonic concentration of said amino acid with respect to the cells, separating the cells from the resulting supernatant and isolating an antigenic preparation containing ACAP from the supernatant.

### Claim 12 (depends on 11)

A method according to claim 11 wherein the amino acid is selected from glycine and alanine.

### Claim 13 (depends on 11)

A method according to claim 11 wherein the said isolation from the supernatant comprises ion exchange chromatography.

### Claim 14 (depends on 11)

A method according to claim 11 wherein the said isolation from the supernatant comprises isoelectric focussing.

### Claim 15 (depends on 13, 14)

A method to either of claims 13 and 14 wherein the said isolation further comprises passage of the isolated material through an immunosorbent column comprising an appropriate monoclonal antibody against the said ACAP.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A vaccine formulation according to any of claims 1 to 10 wherein the said ACAP is prepared by a method according to any of claims 11 to 15.

### Claim 17

ACAP.

### Claim 18 (depends on 21)

Proteinaceous material according to claim 21 characterised in that it has the following properties:-
(i) A ratio of proline to glutamic acid of substantially 1:1;
(ii) the tyrosine residues are not iodinatable;
(iii) substantially free from intracellular, B.pertussis material;
(iv) a relative molecular weight of 67,000 to 73,000;
(v) an isoelectric point of 7.0 to 7.4, and
(vi) being acid-labile below a pH of about 3.

### Claim at position 19 (depends on 17, 18)

19 A method for inducing immunity to whooping cough in a susceptible vertebrate host comprising the administration of ACAP as claimed in either of claims 17 and 18.

### Claim 20 (depends on 19)

A method according to claim 19 wherein the said ACAP is in the form of a vaccine.

### Claim 21 (depends on 19)

A method according to claim 19 wherein the said ACAP is in the form of a vaccine and the host is human.
